Literature DB >> 17659581

Hepatitis C virus quasispecies in HIV-infected women: role of injecting drug use and highly active antiretroviral therapy (HAART).

Tomasz Laskus1, Jeffrey Wilkinson, Roksana Karim, Wendy Mack, Marek Radkowski, Marina deGiacomo, Jonathan Nasseri, Zhi Chen, Jiaao Xu, Andrea Kovacs.   

Abstract

UNLABELLED: Despite the high frequency of HCV and HIV coinfection, little is known about HCV quasispecies in HIV-positive patients. The current analysis included 236 HIV+/anti-HCV+ women enrolled in the Women's Interagency HIV Study (WIHS). Hypervariable region 1 of the second envelope gene was analyzed by single-strand conformation polymorphism (SSCP). The relationship between the HCV quasispecies and clinical and demographic features were analyzed in multivariate models. Age over 40 years and high HCV RNA load were the only factors significantly associated with quasispecies complexity, assessed as the number of SSCP bands. High HIV and HCV plasma loads were associated with quasispecies stability over time, as reflected by stable SSCP band patterns. However, women who were actively injecting drugs were 3 times more likely to experience quasispecies changes than their noninjecting counterparts. No affect on HCV quasispecies dynamics was noted in relation to CD4 count or highly active antiretroviral therapy (HAART).
CONCLUSION: among HIV/HCV coinfected patients, HCV quasispecies complexity and dynamics correlate more closely with HIV and HCV plasma loads than with CD4+ cell counts. Active drug use is associated with quasispecies changes probably due to repeated superinfections with new HCV strains. This needs to be considered when planning treatment and prevention strategies for HCV in coinfected individuals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17659581      PMCID: PMC3508063          DOI: 10.1002/hep.21715

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  70 in total

1.  The effect of drug-injection behavior on genetic evolution of HIV-1.

Authors:  M Carneiro; X F Yu; C Lyles; A Templeton; A E Weisstein; M Safaeian; H Farzadegan; D Vlahov; R B Markham
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

Review 2.  Prospects for a vaccine against the hepatitis C virus.

Authors:  Michael Houghton; Sergio Abrignani
Journal:  Nature       Date:  2005-08-18       Impact factor: 49.962

3.  Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome.

Authors:  Patrizia Farci; Rita Strazzera; Harvey J Alter; Stefania Farci; Daniela Degioannis; Alessandra Coiana; Giovanna Peddis; Francesco Usai; Giancarlo Serra; Luchino Chessa; Giacomo Diaz; Angelo Balestrieri; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-05       Impact factor: 11.205

4.  Clinical and therapeutic implications of hepatitis C virus compartmentalization.

Authors:  Gaëtana Di Liberto; Anne-Marie Roque-Afonso; Rachid Kara; Delphine Ducoulombier; Guillaume Fallot; Didier Samuel; Cyrille Feray
Journal:  Gastroenterology       Date:  2006-07       Impact factor: 22.682

5.  Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group.

Authors:  Y Benhamou; M Bochet; V Di Martino; F Charlotte; F Azria; A Coutellier; M Vidaud; F Bricaire; P Opolon; C Katlama; T Poynard
Journal:  Hepatology       Date:  1999-10       Impact factor: 17.425

6.  Protection against persistence of hepatitis C.

Authors:  Shruti H Mehta; Andrea Cox; Donald R Hoover; Xiao-Hong Wang; Qing Mao; Stuart Ray; Steffanie A Strathdee; David Vlahov; David L Thomas
Journal:  Lancet       Date:  2002-04-27       Impact factor: 79.321

7.  Influence of CD4 cell counts on the genetic heterogeneity of hepatitis C virus in patients coinfected with human immunodeficiency virus.

Authors:  Anne Marie Roque-Afonso; Mathieu Robain; Danielle Simoneau; Patricia Rodriguez-Mathieu; Michèle Gigou; Laurence Meyer; Elisabeth Dussaix
Journal:  J Infect Dis       Date:  2002-02-28       Impact factor: 5.226

8.  HIV infection and antiretroviral therapy: effect on hepatitis C virus quasispecies variability.

Authors:  Margaret C Shuhart; Daniel G Sullivan; Kirubeal Bekele; Robert D Harrington; Mari M Kitahata; Terri L Mathisen; Lisa V Thomassen; Scott S Emerson; David R Gretch
Journal:  J Infect Dis       Date:  2006-03-28       Impact factor: 5.226

9.  HCV quasispecies evolution: association with progression to end-stage liver disease in hemophiliacs infected with HCV or HCV/HIV.

Authors:  Hongxing Qin; Norah J Shire; Erica D Keenan; Susan D Rouster; M Elaine Eyster; James J Goedert; Margaret James Koziel; Kenneth E Sherman
Journal:  Blood       Date:  2004-09-16       Impact factor: 22.113

10.  Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects.

Authors:  Raymond T Chung; Scott R Evans; Yijun Yang; Dickens Theodore; Hernan Valdez; Rebecca Clark; Cecilia Shikuma; Thomas Nevin; Kenneth E Sherman
Journal:  AIDS       Date:  2002-09-27       Impact factor: 4.177

View more
  6 in total

1.  Specific human leukocyte antigen class I and II alleles associated with hepatitis C virus viremia.

Authors:  Mark H Kuniholm; Andrea Kovacs; Xiaojiang Gao; Xiaonan Xue; Darlene Marti; Chloe L Thio; Marion G Peters; Norah A Terrault; Ruth M Greenblatt; James J Goedert; Mardge H Cohen; Howard Minkoff; Stephen J Gange; Kathryn Anastos; Melissa Fazzari; Tiffany G Harris; Mary A Young; Howard D Strickler; Mary Carrington
Journal:  Hepatology       Date:  2010-05       Impact factor: 17.425

2.  The relation of HLA genotype to hepatitis C viral load and markers of liver fibrosis in HIV-infected and HIV-uninfected women.

Authors:  Mark H Kuniholm; Xiaojiang Gao; Xiaonan Xue; Andrea Kovacs; Darlene Marti; Chloe L Thio; Marion G Peters; Ruth M Greenblatt; James J Goedert; Mardge H Cohen; Howard Minkoff; Stephen J Gange; Kathryn Anastos; Melissa Fazzari; Mary A Young; Howard D Strickler; Mary Carrington
Journal:  J Infect Dis       Date:  2011-06-15       Impact factor: 5.226

Review 3.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

4.  Hepatitis C virus (HCV) quasispecies complexity and selection in HCV/HIV-coinfected subjects treated with interferon-based regimens.

Authors:  Kenneth E Sherman; Susan D Rouster; Sandra Stanford; Jason T Blackard; Norah Shire; Margaret Koziel; Marion Peters; Raymond T Chung
Journal:  J Infect Dis       Date:  2010-03       Impact factor: 5.226

5.  Within-host dynamics of the hepatitis C virus quasispecies population in HIV-1/HCV coinfected patients.

Authors:  Flavia Bernini; Erika Ebranati; Chiara De Maddalena; Renata Shkjezi; Laura Milazzo; Alessandra Lo Presti; Massimo Ciccozzi; Massimo Galli; Gianguglielmo Zehender
Journal:  PLoS One       Date:  2011-01-31       Impact factor: 3.240

6.  Multisite prospective Liver Disease and Reproductive Ageing (LIVRA) study in US women living with and without HIV.

Authors:  Jennifer Price; Yifei Ma; Adaora Adimora; Margaret Fischl; Audrey L French; Elizabeth T Golub; Deborah Konkle-Parker; Mark H Kuniholm; Ighovwerha Ofotokun; Michael Plankey; Anjali Sharma; Phyllis C Tien
Journal:  BMJ Open       Date:  2022-04-07       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.